FMC (FMC) Q2 2026 Earnings Call Transcript

FMC reported Q1 revenue of $762M, down 4% YoY but $12M above the guidance midpoint, while adjusted EBITDA of $72M beat the high end by $17M. Full-year guidance was maintained but implies deterioration: revenue $3.6B–$3.8B (-5% at midpoint) and adjusted EPS $1.63–$1.89 (-41% at midpoint) driven by lower EBITDA and ~$25M higher interest expense. Management reiterated its ~$1B 2026 debt reduction plan (incl. India asset divestiture) but flagged cost uncertainty from Iran conflict/trade actions and maintained cautious outlook as free cash flow is expected to range from -$65M to +$65M for 2026.

Analysis

FMC’s setup is less about near-term demand and more about capital structure friction. The equity is being asked to underwrite a multi-quarter transition where the company is still funding restructuring, carrying elevated borrowings, and trying to monetize assets into a softer ag-cycle; that combination usually keeps the multiple capped even if headline EBITDA bottoms. The cleaner read is that the balance sheet is now the main operating variable: every delay in asset sales or refinancing pushes more value from equity to creditors, while a clean India close and bond takeout could force a sharp short-covering rally.

The second-order competitive effect is that FMC is effectively choosing between margin and share in legacy insecticides while trying to re-price itself into premium formulations. If that strategy works, the real loser is not just generic suppliers but also adjacent chemistries that lose share in North America and Brazil as growers consolidate around higher-efficacy mixes. The winner on the supply chain side is lower-cost Asian manufacturing, which should structurally squeeze older Western plants and any peer still tied to high-cost production.

The contrarian point is that consensus may be overweighting the patent expiry and underweighting the timing of pricing stabilization. The most important tell over the next 1-3 months is whether partner pricing and generic prices stop falling before the H2 sell-in window; if so, FY26 could look less like a collapse and more like a trough year. Over 6-18 months, the real upside case is not cyclical recovery but a balance-sheet re-rate if new active ingredients scale and leverage falls quickly enough to remove covenant anxiety.

Key Decisions for Investors

• Short FMC on any post-earnings relief rally; 3-6 month horizon. Thesis: negative/near-zero FCF plus 5x+ net leverage keeps the equity capped until asset monetization is proven. Cover if India closes definitively and the company pre-funds the October maturity without widening credit spreads.
• Pair trade: long CTVA / short FMC for 3-6 months. FMC has more balance-sheet and patent-transition risk, while CTVA should be less sensitive to a single-product cliff and refinancing headlines. Falsifier: FMC delivers two consecutive quarters of stable partner pricing and >$700M of signed asset-sale proceeds.
• Buy FMC put spreads only after a squeeze-driven move higher, targeting the next catalyst window around Q2/Q3 order confirmation. This is a tactical hedge against a reset in H2 expectations if Brazil orders or Rynaxypyr mix fail to hold.
• Watch item, not a trade yet: secured bond pricing and CDS/spread behavior into the planned refinancing. A tighter-than-expected issue would be the cleanest signal that equity downside from the capital structure is becoming less acute.